RETINOID HEPATITIS

A 65-year-old woman treated with etretinate for pityriasis rubra pilar is developed chronic active hepatitis. The elevated transaminases were noted 2 months after initiation of therapy and peaked 2 months after discontinuation of etretinate. The spectrum of liver toxicity induced by etretinate is reviewed. We suggest that reported cases of retinoid- induced liver disease can be divided into four distinct categories: no nspecific reactive hepatitis, acute hepatitis, chronic active hepatiti s, and severe fibrosis or cirrhosis.